WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index
MWN-AI** Summary
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has been recognized for its sustainability efforts by being included in the 2025 Hang Seng Corporate Sustainability Benchmark Index. Notably, it is the only pharmaceutical company to be selected for this prestigious index, which highlights publicly listed entities demonstrating exceptional Environmental, Social, and Governance (ESG) performance.
In addition to this recognition, WuXi Biologics is also part of the HSI ESG Index and the Hang Seng ESG 50 Index. The Hang Seng Corporate Sustainability Benchmark Index is compiled through a rigorous evaluation process conducted by the Hong Kong Quality Assurance Agency (HKQAA), which assesses companies on their sustainability practices.
WuXi Biologics has distinguished itself as a provider of sustainable biologics solutions, with a commitment to green research, energy efficiency, and transparent governance. The company's CEO, Dr. Chris Chen, emphasized that this inclusion reflects WuXi's ongoing commitment to sustainability and creating long-term value for its stakeholders and society. Aligning with the United Nations Sustainable Development Goals, WuXi Biologics has set ambitious greenhouse gas emissions-reduction targets, approved by the Science Based Targets initiative.
The company's sustainability achievements are widely recognized, including an MSCI AAA ESG rating, EcoVadis Platinum Medal, and a top rating from Sustainalytics. As of mid-2025, WuXi Biologics supports 864 integrated client projects, demonstrating its significant role in the biologics industry while prioritizing sustainability as a core component of its growth strategy. The commitment to responsible business practices positions WuXi Biologics as a leader in the global market, reinforcing its pivotal role in promoting environmental stewardship and social responsibility.
MWN-AI** Analysis
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has recently earned its place in the prestigious Hang Seng Corporate Sustainability Benchmark Index, marking it as the sole pharmaceutical company included in the metric. This recognition underscores the firm's commitment to sustainability practices, enhancing its profile in an increasingly ESG-oriented investment landscape.
The inclusion in not only the Hang Seng Corporate Sustainability Benchmark Index but also the HSI ESG Index and Hang Seng ESG 50 Index reflects a robust evaluation of WuXi's operations, which prioritize sustainability through efficient resource management, transparency, and strong employee welfare initiatives. Investors should take note of this growing trend, as more capital is being funneled towards companies demonstrating strong Environmental, Social, and Governance (ESG) performance. WuXi Biologics’ consistent commitment to sustainability through advanced green technology aligns well with investor preferences for socially responsible companies.
Additionally, the company’s recent partnership with the United Nations Global Compact and its ambitious greenhouse gas emissions-reduction target, verified by the Science Based Targets initiative, position WuXi favorably for both regulatory compliance and investor confidence. The various accolades it has received—including an MSCI AAA ESG Rating and recognition in multiple sustainability indices—further solidify its reputation as a leader in responsible business practices.
Given WuXi Biologics’ strong performance and significant role in the biopharmaceutical sector, it is recommended for investors seeking exposure to sustainable assets. The firm’s proactive approach to ESG not only enhances its brand value but potentially mitigates regulatory risks while driving long-term, sustainable growth. As the global market increasingly values sustainable business practices, WuXi Biologics appears to be a compelling addition to an investor’s portfolio.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
- The only company from pharmaceutical industry selected for inclusion in the Index
- Also included in HSI ESG Index and Hang Seng ESG 50 Index
- Green CRDMO solution provider with outstanding sustainability performance
HONG KONG, Oct. 21, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced its inclusion in the 2025 Hang Seng Corporate Sustainability Benchmark Index. It stands out as the only company from the pharmaceutical industry selected for this prestigious recognition. The company has also been previously honored for its inclusion in both the HSI ESG Index and the Hang Seng ESG 50 Index.
The Hang Seng Corporate Sustainability Benchmark Index recognizes publicly listed companies that demonstrate outstanding ESG performance, providing benchmarks for sustainability investments. Constituent selection follows a comprehensive process based on the results from a sustainability assessment undertaken annually by the Hong Kong Quality Assurance Agency (HKQAA), an independent and professional assessment body, using its proprietary sustainability assessment and rating framework.
As a global provider of biologics Green CRDMO solutions, WuXi Biologics has consistently embraced sustainability principles as integral to its robust business growth — advancing sustainable practices in biologics green research, development, manufacturing, and operations; optimizing energy and resource efficiency; enhancing governance transparency; and demonstrating unwavering dedication to employee welfare and societal improvement.
Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, "Being included in the Hang Seng Indexes is a significant recognition of our continuous efforts in pursuing sustainability. As a global leader in Green CRDMO, we will remain committed to creating long-term value for stakeholders while contributing to society and the environment."
In line with the United Nations Sustainable Development Goals, WuXi Biologics has been actively engaged with the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI). The company's new near-term and net-zero greenhouse gas emissions-reduction target matrix has been approved by the Science Based Targets initiative (SBTi) in August.
Over the past few years, WuXi Biologics has earned widespread recognition for its dedicated efforts in sustainability. The company was granted MSCI AAA ESG Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to CDP Water Security "A List" and Supplier Engagement Assessment "A List", and awarded a CDP Climate Change leadership-level "A-" score; given the highest negligible-risk rating by Sustainalytics, and recognized as a Sustainalytics industry and regional ESG top-rated company; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2025, WuXi Biologics is supporting 864 integrated client projects, including 24 in commercial manufacturing.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
Contacts
Media
PR@wuxibiologics.com
SOURCE WuXi Biologics
FAQ**
How does WuXi Biologics Cayman Inc ADR WXXWY plan to leverage its inclusion in the Hang Seng Corporate Sustainability Benchmark Index to attract new investors focused on ESG performance?
What specific sustainability initiatives contributed to WuXi Biologics Cayman Inc ADR WXXWY's selection as the only pharmaceutical company in this prestigious index?
How is WuXi Biologics Cayman Inc ADR WXXWY addressing the challenges of maintaining green practices while scaling operations to support its 864 client projects?
In what ways does WuXi Biologics Cayman Inc ADR WXXWY engage stakeholders to enhance its sustainability performance and align with the United Nations Sustainable Development Goals?
**MWN-AI FAQ is based on asking OpenAI questions about Wuxi Biologics Cayman Inc ADR (OTC: WXXWY).
NASDAQ: WXXWY
WXXWY Trading
-3.38% G/L:
$8.792 Last:
11,387 Volume:
$8.96 Open:
